- STAT+: Pharma tries to tamp down broad China restrictionsAI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The ReadoutSTAT · 6d ago↗ source
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.BioSpace · 6d ago↗ source
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…BioPharma Dive